18F-fluorodeoxyglucose positron emission/computed tomography (18F-FDG PET/CT) imaging, an established procedure for evaluation of malignancy, shows an increased 18F-FDG uptake in inflammatory conditions. We present three patients with abdominal pain and weight loss. Conventional imaging studies indicated that abdominal neoplasm and 18F-FDG PET/CT for assessment of malignancy showed multiple lesions with intense 18F-FDG uptake in abdomen of the three cases. However, the three patients were finally diagnosed with multi-site abdominal tuberculosis (TB). Of them, two were diagnosed with TB by pathology, one was diagnosed with TB clinically. They recovered after anti-TB therapy. Few reports on accumulation of 18F-FDG in abdominal TB are available in the literature. A high index of suspicion is necessary to achieve an early diagnosis and a better outcome of the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932932 | PMC |
| http://dx.doi.org/10.3748/wjg.v16.i33.4237 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The predictive power of F-FDG PET/CT two-lesions radiomics and conventional models in classical Hodgkin's Lymphoma: a comparative retrospectively-validated study.
Ann Hematol
January 2025
Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
In a previous preliminary study, radiomic features from the largest and the hottest lesion in baseline F-FDG PET/CT (bPET/CT) of classical Hodgkin's Lymphoma (cHL) predicted early response-to-treatment and prognosis. Aim of this large retrospectively-validated study is to evaluate the predictive role of two-lesions radiomics in comparison with other clinical and conventional PET/CT models. cHL patients with bPET/CT between 2010 and 2020 were retrospectively included and randomized into training-validation sets.
View Article and Find Full Text PDFPET/CT-based target volume definition in involved-site radiotherapy for treatment of early-stage nodal follicular lymphoma.
Strahlenther Onkol
January 2025
Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Purpose: Recent advancements in imaging, particularly 18F-fluorodeoxyglucose positron-emission tomography-computed tomography (FDG-PET/CT), have improved the detection of involved lymph nodes, thus influencing staging accuracy and potentially treatment outcomes. This study is a post hoc analysis of the GAZAI trial data to evaluate the impact of FDG-PET/CT versus computed tomography (CT) alone on radiation target volumes for involved-site radiotherapy (IS-RT) in early-stage follicular lymphoma (FL).
Methods: All patients in the GAZAI trial underwent pretherapeutic FDG-PET/CT examinations, which were subject to central quality control.
F-FAPI-42 PET/CT and F-FDG PET/CT in Patients with Malignant Digestive System Neoplasms: A Head-to-Head Comparative Study.
Mol Imaging Biol
January 2025
Department of Nuclear Medicine, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Purpose: Radionuclide-labeled fibroblast activation protein inhibitor (FAPI) is an emerging tumor tracer. We sought to assess the uptake and diagnostic performance of F-FAPI-42 PET/CT compared with simultaneous 2-deoxy-2[F]fluoro-D-glucose (F-FDG) PET/CT in primary and metastatic lesions in patients with malignant digestive system neoplasms and to determine the potential clinical benefit.
Procedures: Forty-two patients (men = 30, women = 12, mean age = 56.
Exploring the Role of [Ga]Ga-DOTAGA-IAC and Comparison of Its Diagnostic Performance with [F]F-FDG PET/CT in Radioiodine Refractory Differentiated Thyroid Carcinoma.
Cancer Biother Radiopharm
January 2025
Advanced Innovative Partners, Inc. (AIP), Miami, Florida, USA.
Integrin antagonist complex (IAC), a novel αvβ3 integrin antagonist peptidomimetic, has emerged as a promising agent for molecular imaging of tumor angiogenesis. This study evaluates the biodistribution and clinical efficacy of [Ga]Ga-DOTAGA-IAC PET/CT in detecting radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), comparing its diagnostic performance with [F]F-FDG PET/CT. In this prospective pilot study, RAIR-DTC patients underwent whole-body imaging with [F] F-FDG PET/CT, followed by [Ga]Ga-DOTAGA-IAC PET/CT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!